Skip to Main Content

Paper Details

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Cancer Res Commun
1
2023
AKT, AR, ARPC, ASCL1, Achaete-scute homolog 1, CRPC, Castration-resistant and Neuroendocrine Prostate Cancers, Castration-resistant prostate cancer, Fimepinostat, HDAC, HDAC1/2, Histone, NEPC, PI3K, Tumor cells, androgen, androgen receptor, androgen receptor (AR)-active prostate cancer, cancer, cancer cell, cell line, chromatin, fimepinostat, histone deacetylase, mTOR, neuroendocrine prostate cancer, patient, patients, prostate cancer, tumor, tumors
Author NameAffiliation
Ilsa ColemanFred Hutchinson Cancer Center
Eva CoreyUniversity of Washington School of Medicine
Joshi J AlumkalRogel Cancer Center, University of Michigan ann arbor
Peter S NelsonFred Hutchinson Cancer Center
Peter S NelsonUniversity of Washington School of Medicine
Peter S NelsonDivision of Clinical Research, Fred Hutchinson Cancer Center
Peter S NelsonFred Hutchinson Cancer Center
Peter S NelsonUniversity of Washington School of Medicine
Peter S NelsonDivision of Clinical Research, Fred Hutchinson Cancer Center
Colm MorrisseyUniversity of Washington School of Medicine
  • 1 - 10

Datasets

Release 1.2